Developing a new imaging device for targeted cancer therapy
Official title: AC-225 Imaging R01 Transfer
Funded at University of Calif-Lawrenc Berkeley Lab · NIH-11159270 · Data updated 2026-11-12
This study is working on a new imaging device to help doctors see how a special cancer treatment, using a substance called 225Ac, moves around in the body, which could lead to better therapies for patients with acute myeloid leukemia and other cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Calif-Lawrenc Berkeley Lab NIH-funded |
| Lab location | 1 site (Berkeley, United States) |
| Project start | September 30, 2022 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,043,907 |
| NIH project number | 7R01EB032324-03 |
| Project ID | NIH-11159270 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute myeloid leukemia or other cancers that may benefit from targeted alpha therapy.
✕Less likely to help
Patients with cancers that do not respond to targeted alpha therapy or those who are not eligible for imaging studies may not benefit from this research.
What this research studies
This research focuses on creating an advanced gamma imaging device that combines innovative reconstruction techniques to enhance the sensitivity of imaging 225Ac, a promising isotope used in targeted alpha therapy for cancer treatment. By enabling in vivo imaging of this isotope, the project aims to improve the understanding of how radiopharmaceuticals distribute within the body, particularly in patients with acute myeloid leukemia and other malignancies. The goal is to facilitate the development and FDA approval of new treatments by providing better insights into the pharmacokinetics of these therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted cancer treatments with fewer side effects for patients.
How similar studies have gone: Previous research has shown promising results with targeted alpha therapy in treating various malignancies, indicating potential success for this novel imaging approach.
Where this research is happening
-
University of Calif-Lawrenc Berkeley Lab
Berkeley, United States Active
Researchers
- Principal investigator: Caravaca, Javier — University of Calif-Lawrenc Berkeley Lab
- Study coordinator: Caravaca, Javier
Related research
Other NIH-funded projects on the same topics.
-
A PET marker to study myelin and brain wiring in aging and Alzheimer’s disease
This study tests a new PET tracer to see how myelin health relates to aging and Alzheimer’s disease in people who may be at risk or affected.
-
Structural Cell Biology Core for DNA Damage Response in Cancer
A core facility at a major university will provide advanced structural biology and AI-enabled imaging tools to study how DNA damage response proteins assemble and work in cancer cells.
-
EMB Core at UC Berkeley boosts DNA repair protein research
A core laboratory at UC Berkeley is expanding its methods to produce high-quality DNA repair proteins and complexes, using advanced gene editing to study human cell lines.
-
Regulation of double-strand break repair during replication stress
Aims to understand how human cells decide between safe and risky DNA repair during replication stress, which could influence cancer development and treatment.
-
Mechanisms of single-strand DNA break repair and how PAR chains regulate them
A large, multi-institutional project is exploring how cells fix single-strand DNA breaks and how the PARP system influences this process, with implications for improving cancer treatments.
-
Understanding how ERCC1-XPF is turned on to fix damaged DNA in cancer-related pathways
A researchers team is studying how a DNA-cutting enzyme (ERCC1-XPF) is activated in damaged DNA repair pathways to better understand cancer and responses to chemotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.